Literature DB >> 1337182

Predicting progression in membranous glomerulonephritis.

D C Cattran1, Y Pei, C Greenwood.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1337182

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  7 in total

1.  Patients with primary membranous nephropathy are at high risk of cardiovascular events.

Authors:  Taewoo Lee; Vimal K Derebail; Abhijit V Kshirsagar; Yunro Chung; Jason P Fine; Shannon Mahoney; Caroline J Poulton; Sophia Lionaki; Susan L Hogan; Ronald J Falk; Daniel C Cattran; Michelle Hladunewich; Heather N Reich; Patrick H Nachman
Journal:  Kidney Int       Date:  2016-02-26       Impact factor: 10.612

Review 2.  [Membranous glomerulonephritis].

Authors:  S Scheidat; R A K Stahl
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

3.  Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.

Authors:  Maria V Irazabal; Alfonso Eirin; John Lieske; Laurence H Beck; Sanjeev Sethi; Timothy M Borland; John J Dillon; Patrick H Nachman; Samih H Nasr; Lynn D Cornell; Nelson Leung; Daniel C Cattran; Fernando C Fervenza
Journal:  Nephrol Dial Transplant       Date:  2012-09-17       Impact factor: 5.992

Review 4.  Controversies in the treatment of idiopathic membranous nephropathy.

Authors:  Meryl Waldman; Howard A Austin
Journal:  Nat Rev Nephrol       Date:  2009-07-07       Impact factor: 28.314

5.  Glomerular endothelial cell injury and focal segmental glomerulosclerosis lesion in idiopathic membranous nephropathy.

Authors:  Megumi Morita; Akiko Mii; Akira Shimizu; Fumihiko Yasuda; Jun Shoji; Yukinari Masuda; Ryuji Ohashi; Kiyotaka Nagahama; Tomohiro Kaneko; Shuichi Tsuruoka
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

6.  Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.

Authors:  Frank B Cortazar; David E Leaf; Charles T Owens; Karen Laliberte; William F Pendergraft; John L Niles
Journal:  BMC Nephrol       Date:  2017-02-01       Impact factor: 2.388

7.  Management of anticoagulation and antiplatelet therapy in patients with primary membranous nephropathy.

Authors:  Honghong Zou; Yebei Li; Gaosi Xu
Journal:  BMC Nephrol       Date:  2019-12-02       Impact factor: 2.388
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.